MiMedx Group Inc (MDXG) : Mycio Wealth Partners reduced its stake in MiMedx Group Inc by 1.71% during the most recent quarter end. The investment management company now holds a total of 368,570 shares of MiMedx Group Inc which is valued at $2,771,646 after selling 6,430 shares in MiMedx Group Inc , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.MiMedx Group Inc makes up approximately 0.46% of Mycio Wealth Partners’s portfolio.
Other Hedge Funds, Including , Swiss National Bank boosted its stake in MDXG in the latest quarter, The investment management firm added 16,200 additional shares and now holds a total of 172,700 shares of MiMedx Group Inc which is valued at $1,303,885. Sigma Planning Corp sold out all of its stake in MDXG during the most recent quarter. The investment firm sold 12,740 shares of MDXG which is valued $99,117.Summit Creek Advisors boosted its stake in MDXG in the latest quarter, The investment management firm added 78,709 additional shares and now holds a total of 1,244,200 shares of MiMedx Group Inc which is valued at $9,679,876. MiMedx Group Inc makes up approx 1.57% of Summit Creek Advisors’s portfolio. Barrett Asset Management sold out all of its stake in MDXG during the most recent quarter. The investment firm sold 727 shares of MDXG which is valued $5,707.
MiMedx Group Inc closed down -0.04 points or -0.54% at $7.3 with 3,32,592 shares getting traded on Friday. Post opening the session at $7.32, the shares hit an intraday low of $7.21 and an intraday high of $7.335 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, MiMedx Group Inc reported $0.05 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Jul 26, 2016. Analyst had a consensus of $0.07. The company had revenue of $57.34 million for the quarter, compared to analysts expectations of $56.20 million. The company’s revenue was up 25.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.05 EPS.
MiMedx Group Inc. (MiMedx) is an integrated developer manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Company’s biomaterial platform technologies include AmnioFix and EpiFix its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant which is referred as an allograft. MiMedx is the supplier of amniotic tissue having supplied over 350000 allografts for application in the Wound Care Surgical Sports Medicine Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.